Актуальность

oncotomsk

Сибирский онкологический журнал

Siberian journal of oncology

1814-48612312-3168

Tomsk National Research Medical Сепtеr of the Russian Academy of Sciences

10.21294/1814-4861-2023-22-5-134-144

oncotomsk-2767

Research Article

ОБЗОРЫ

REVIEWS

Исследование новых биомаркеров, связанных с множественной миеломой

A study to identify novel biomarkers associated with multiple myeloma

https://orcid.org/0000-0001-9368-3434

Iyshwarya

Bhaskar Kalarani

Iyshwarya

Bhaskar Kalarani

Iyshwarya Bhaskar Kalarani - младший научный сотрудник факультета смежных медицинских наук.

Четтинад, Келамбаккам, 603103, Тамилнаду

Iyshwarya Bhaskar Kalarani - Junior Research Fellow, Faculty of Allied Health Sciences, Author ID (Scopus): 57475835600.

Kelambakkam, 603103, Tamilnadu

https://orcid.org/0000-0002-9307-5428

Ramakrishnan

Veerabathiran

Ramakrishnan

Veerabathiran

Ramakrishnan Veerabathiran - доцент кафедры генетики факультета смежных медицинских наук.

Четтинад, Келамбаккам, 603103, Тамилнаду

Ramakrishnan Veerabathiran - Associate Professor in Genetics, Faculty of Allied Health Sciences, Author ID (Scopus): 55632777000.

Kelambakkam, 603103, Tamilnadu

rkgenes@gmail.com

Академия высшего образования и исследований, больница и научно-исследовательского института ЧеттинадИндияChettinad Hospital and Research Institute, Chettinad Academy of Research and EducationIndia

2023

16112023

225134144

2023

Iyshwarya B., Ramakrishnan V.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.siboncoj.ru/jour/article/view/2767

Актуальность

Актуальность. Множественная миелома (ММ) – злокачественная опухоль плазматических клеток, поражающая лейкоциты. У пациентов с ММ аномалии в плазматических клетках костного мозга приводят к повышению уровня моноклонального иммуноглобулина в крови и моче, с развитием почечной недостаточности и появлению рецидивирующих инфекций. Остеолитические поражения и иммунодефицит также оказывают негативное влияние на продолжительность и качество жизни пациентов с множественной миеломой. На это заболевание приходится 13 % всех злокачественных гематологических опухолей в мире, что делает ММ вторым наиболее распространенным новообразованием кроветворной системы.

Материал и методы

Материал и методы. В различных базах данных проведен поиск опубликованных результатов исследований, посвященных биомаркерам ММ, за период с 2000 по 2021 г. При отборе статей использовались следующие ключевые понятия: «множественная миелома», «биомаркеры», «генетические маркеры», «прогностические маркеры», «эпидемиология множественной миеломы», «факторы риска множественной миеломы».

Результаты

Результаты. Несмотря на значительные успехи, полученные в изучении и лечении ММ, число больных с этой патологией продолжает расти, побуждая исследователей к поиску новых маркеров для прогноза, диагностики и лечения заболевания, особенно на ранних стадиях. Прогностические и предиктивные факторы риска рецидива заболевания и ответа на терапию могут быть выявлены с помощью более эффективных инновационных методов определения потенциальных биомаркеров.

Заключение

Заключение. Несмотря на применение различных противоопухолевых препаратов, включая иммуномодуляторы и ингибиторы протеасом при лечении множественной миеломы, у большинства пациентов наблюдаются рецидивы заболевания. В обзоре проанализированы современные методы лечения множественной миеломы, как наиболее часто используемые, так и новые, представленные в недавно опубликованных статьях.

Background

Background. multiple myeloma (mm) is a plasma cell cancer that affects white blood cells. plasma cells from the bone marrow grow abnormally, as a consequence of which patients have high amounts of monoclonal immunoglobulin in their blood and urine, poor renal function, and recurring infections due to this condition. osteolytic bone lesions and immunodeficiency also impact multiple myeloma patients’ longevity and quality of life. The disease accounts for 13 % of all hematological malignancies worldwide, making it the second most common blood cancer.

Material and Methods

Material and Methods. The studies investigating mm biomarkers from 2000 to 2021 are collected from various databases. “multiple myeloma”, “biomarkers”, “genetic markers”, “prognostic markers”, “epidemiology of multiple myeloma”, and “risk factors for multiple myeloma” are the key phrases utilized to gather the articles.

Results

Results. The scientific and medical research progressed into mm, and the number of cases increased over time and continues to rise, prompting researchers and clinicians to discover new consequences of the disease and new markers for prognosis, diagnosis, detection, and treatment of cancer in the earliest stages. Prognostic and predictive signs for illness recurrence and response to medication may be detected adequately by innovative potential biomarkers, which are more accurate than current approaches.

Conclusion

Conclusion. treatment for multiple myeloma includes a variety of chemotherapeutic medicines, including immune modulators and proteasome inhibitors; however, most patients still experience recurrence after completing treatment. There have been numerous novel techniques for managing multiple myeloma, and this review summarises the most commonly used and the new ones that have appeared in the previously published articles.

множественная миеломабиомаркерытерапевтические мишенипрогноз

multiple myelomabiomarkerstherapeutic targetsprognosis

References1

Gonsalves W.I., Gertz M.A., Gupta V., Rajkumar S.V. Prognostic Significance of Quantifying Circulating Plasma Cells in Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2014; 14: 147. doi: 10.1016/j.clml.2014.06.087.

Gupta N., Sharma A., Sharma A. Emerging biomarkers in Multiple Myeloma: A review. Clin Chim Acta. 2020; 503: 45–53. doi: 10.1016/j.CCa.2019.12.026.

Cid Ruzafa J., Merinopoulou E., Baggaley R.F., Leighton P., Werther W., Felici D., Cox A. Patient population with multiple myeloma and transitions across different lines of therapy in the USA: an epidemiologic model. Pharmacoepidemiol Drug Saf. 2016; 25(8): 871–9. doi: 10.1002/pds.3927.

Peña C., Rojas C., Rojas H., Soto P., Cardemil D., Aranda S., Contreras C., La Roca G., Russo M., Pérez C., Lois V. Mieloma múltiple en Chile: pasado, presente y futuro del programa nacional de drogas antineoplásicas (PANDA). Revisión de 1.103 pacientes [Survival of 1,103 Chilean patients with multiple myeloma receiving different therapeutic protocols from 2000 to 2016]. Rev Med Chil. 2018; 146(7): 869–75. Spanish. doi: 10.4067/s0034-98872018000700869.

Bolli N., Maura F., Minvielle S., Gloznik D., Szalat R., Fullam A., Martincorena I., Dawson K.J., Samur M.K., Zamora J., Tarpey P., Davies H., Fulciniti M., Shammas M.A., Tai Y.T., Magrangeas F., Moreau P., Corradini P., Anderson K., Alexandrov L., Wedge D.C., Avet-Loiseau H., Campbell P., Munshi N. Genomic patterns of progression in smoldering multiple myeloma. Nat Commun. 2018; 9(1): 3363. doi: 10.1038/s41467-018-05058-y.

Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer, 2020.

Howlader N.N., Noone A.M., Krapcho M.E. et al. SEER cancer statistics review, 1975–2016. National Cancer Institute. 2019 Apr; 1.

Ludwig H., Novis Durie S., Meckl A., Hinke A., Durie B. Multiple Myeloma Incidence and Mortality Around the Globe; Interrelations Between Health Access and Quality, Economic Resources, and Patient Empowerment. Oncologist. 2020; 25(9): 1406–13. doi: 10.1634/theoncologist.2020-0141.

Padala S.A., Barsouk A., Barsouk A., Rawla P., Vakiti A., Kolhe R., Kota V., Ajebo G.H. Epidemiology, Staging, and Management of Multiple Myeloma. Med Sci (Basel). 2021; 9(1): 3. doi: 10.3390/medsci9010003.

Schinasi L.H., Brown E.E., Camp N.J., Wang S.S., Hofmann J.N., Chiu B.C., Miligi L., Beane Freeman L.E., de Sanjose S., Bernstein L., Monnereau A., Clavel J., Tricot G.J., Atanackovic D., Cocco P., Orsi L., Dosman J.A., McLaughlin J.R., Purdue M.P., Cozen W., Spinelli J.J., de Roos A.J. Multiple myeloma and family history of lymphohaematopoietic cancers: Results from the International Multiple Myeloma Consortium. Br J Haematol. 2016; 175(1): 87–101. doi: 10.1111/bjh.14199.

Cowan A.J., Allen C., Barac A., Basaleem H., Bensenor I., Curado M.P., Foreman K., Gupta R., Harvey J., Hosgood H.D., Jakovljevic M., Khader Y., Linn S., Lad D., Mantovani L., Nong V.M., Mokdad A., Naghavi M., Postma M., Roshandel G., Shackelford K., Sisay M., Nguyen C.T., Tran T.T., Xuan B.T., Ukwaja K.N., Vollset S.E., Weiderpass E., Libby E.N., Fitzmaurice C. Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016. JAMA Oncol. 2018; 4(9): 1221–7. doi: 10.1001/jamaoncol.2018.2128.

Waxman A.J., Mink P.J., Devesa S.S., Anderson W.F., Weiss B.M., Kristinsson S.Y., McGlynn K.A., Landgren O. Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood. 2010; 116(25): 5501–6. doi: 10.1182/blood-2010-07-298760.

Baker A., Braggio E., Jacobus S., Jung S., Larson D., Therneau T., Dispenzieri A., Van Wier S.A., Ahmann G., Levy J., Perkins L., Kim S., Henderson K., Vesole D., Rajkumar S.V., Jelinek D.F., Carpten J., Fonseca R. Uncovering the biology of multiple myeloma among African Americans: a comprehensive genomics approach. Blood. 2013; 121(16): 3147–52. doi: 10.1182/blood-2012-07-443606.

Dutta A.K., Fink J.L., Grady J.P., Morgan G.J., Mullighan C.G., To L.B., Hewett D.R., Zannettino A.C.W. Subclonal evolution in disease progression from MGUS/SMM to multiple myeloma is characterised by clonal stability. Leukemia. 2019; 33(2): 457–68. doi: 10.1038/s41375-018-0206-x.

Lorsbach R.B., Hsi E.D., Dogan A., Fend F. Plasma cell myeloma and related neoplasms. Am J Clin Pathol. 2011; 136(2): 168–82. doi: 10.1309/AJCPENJ68FFBRIYB.

Rajkumar S.V., Dimopoulos M.A., Palumbo A., Blade J., Merlini G., Mateos M.V., Kumar S., Hillengass J., Kastritis E., Richardson P., Landgren O., Paiva B., Dispenzieri A., Weiss B., LeLeu X., Zweegman S., Lonial S., Rosinol L., Zamagni E., Jagannath S., Sezer O., Kristinsson S.Y., Caers J., Usmani S.Z., Lahuerta J.J., Johnsen H.E., Beksac M., Cavo M., Goldschmidt H., Terpos E., Kyle R.A., Anderson K.C., Durie B.G., Miguel J.F. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014; 15(12): 538–48. doi: 10.1016/s1470-2045(14)70442-5.

Podar K., Chauhan D., Anderson K.C. Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia. 2009; 23(1): 10–24. doi: 10.1038/leu.2008.259.

Fairfield H., Falank C., Avery L., Reagan M.R. Multiple myeloma in the marrow: pathogenesis and treatments. Ann N Y Acad Sci. 2016; 1364(1): 32–51. doi: 10.1111/nyas.13038.

Gilbert L.C., Chen H., Lu X., Nanes M.S. Chronic low dose tumor necrosis factor-α (TNF) suppresses early bone accrual in young mice by inhibiting osteoblasts without affecting osteoclasts. Bone. 2013; 56(1): 174–83. doi: 10.1016/j.bone.2013.06.002.

Bolli N., Biancon G., MoarII M., Gimondi S., Li Y., de Philippis C., Maura F., Sathiaseelan V., Tai Y.T., Mudie L., O’Meara S., Raine K., Teague J.W., Butler A.P., Carniti C., Gerstung M., Bagratuni T., Kastritis E., Dimopoulos M., Corradini P., Anderson K.C., Moreau P., Minvielle S., Campbell P.J., Papaemmanuil E., Avet-Loiseau H., Munshi N.C. Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. Leukemia. 2018; 32(12): 2604–16. doi: 10.1038/s41375-018-0037-9.

Walker B.A., Mavrommatis K., Wardell C.P., Ashby T.C., Bauer M., Davies F.E., Rosenthal A., Wang H., Qu P., Hoering A., Samur M., Towfic F., Ortiz M., Flynt E., Yu Z., Yang Z., Rozelle D., Obenauer J., Trotter M., Auclair D., Keats J., Bolli N., Fulciniti M., Szalat R., Moreau P., Durie B., Stewart A.K., Goldschmidt H., Raab M.S., Einsele H., Sonneveld P., San Miguel J., Lonial S., Jackson G.H., Anderson K.C., Avet-Loiseau H., Munshi N., Thakurta A., Morgan G.J. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood. 2018; 132(6): 587–97. doi: 10.1182/blood-2018-03-840132. Erratum in: Blood. 2018; 132(13): 1461.

Manier S., Salem K.Z., Park J., Landau D.A., Getz G., Ghobrial I.M. Genomic complexity of multiple myeloma and its clinical implications. Nat Rev Clin Oncol. 2017; 14(2): 100–13. doi: 10.1038/nrclinonc.2016.122.

Morgan G.J., Walker B.A., Davies F.E. The genetic architecture of multiple myeloma. Nat Rev Cancer. 2012; 12(5): 335–48. doi: 10.1038/nrc3257.

Jones W., Alasoo K., Fishman D., Parts L. Computational biology: deep learning. Emerg Top Life Sci. 2017; 1(3): 257–74. doi: 10.1042/ETLS20160025.

Wainberg M., Merico D., Delong A., Frey B.J. Deep learning in biomedicine. Nat Biotechnol. 2018; 36(9): 829–38. doi: 10.1038/nbt.4233.

Zou J., Huss M., Abid A., Mohammadi P., Torkamani A., Telenti A. A primer on deep learning in genomics. Nat Genet. 2019; 51(1): 12–8. doi: 10.1038/s41588-018-0295-5.

Walsh S., de Jong E.E.C., van Timmeren J.E., Ibrahim A., Compter I., Peerlings J., Sanduleanu S., Refaee T., Keek S., Larue R.T.H.M., van Wijk Y., Even A.J.G., Jochems A., Barakat M.S., Leijenaar R.T.H., Lambin P. Decision Support Systems in Oncology. JCO Clin Cancer Inform. 2019; 3: 1–9. doi: 10.1200/CCI.18.00001.

Hemminki K., Försti A., Houlston R., Sud A. Epidemiology, genetics and treatment of multiple myeloma and precursor diseases. Int J Cancer. 2021; 149(12): 1980–96. doi: 10.1002/ijc.33762.

Blimark C.H., Vangsted A.J., Klausen T.W., Gregersen H., Szabo A.G., Hermansen E., Wålinder G., Knut-Bojanowska D., Zang C., Turesson I.; Real-World Evidence Group within the Nordic Myeloma Study Group (NMSG). Outcome data from >10000multiple myeloma patients in the Danish and Swedish national registries. Eur J Haematol. 2022; 108(2): 99–108. doi: 10.1111/ejh.13707.

Miller R.G. Simultaneous Statistical Inference. 2nd ed. New York: Springer Verlag, 1981.

Chapman M.A., Lawrence M.S., Keats J.J., Cibulskis K., Sougnez C., Schinzel A.C., Harview C.L., Brunet J.P., Ahmann G.J., Adli M., Anderson K.C., Ardlie K.G., Auclair D., Baker A., Bergsagel P.L., Bernstein B.E., Drier Y., Fonseca R., Gabriel S.B., Hofmeister C.C., Jagannath S., Jakubowiak A.J., Krishnan A., Levy J., Liefeld T., Lonial S., Mahan S., Mfuko B., Monti S., Perkins L.M., Onofrio R., Pugh T.J., Rajkumar S.V., Ramos A.H., Siegel D.S., Sivachenko A., Stewart A.K., Trudel S., Vij R., Voet D., Winckler W., Zimmerman T., Carpten J., Trent J., Hahn W.C., Garraway L.A., Meyerson M., Lander E.S., Getz G., Golub T.R. Initial genome sequencing and analysis of multiple myeloma. Nature. 2011; 471(7339): 467–72. doi: 10.1038/nature09837.

Lohr J.G., Stojanov P., Carter S.L., Cruz-Gordillo P., Lawrence M.S., Auclair D., Sougnez C., Knoechel B., Gould J., Saksena G., Cibulskis K., McKenna A., Chapman M.A., Straussman R., Levy J., Perkins L.M., Keats J.J., Schumacher S.E., Rosenberg M.; Multiple Myeloma Research Consortium; Getz G., Golub T.R. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell. 2014; 25(1): 91–101. doi: 10.1016/j.ccr.2013.12.015.

McShane L.M., Hayes D.F. Publication of tumor marker research results: the necessity for complete and transparent reporting. J Clin Oncol. 2012; 30(34): 4223–32. doi: 10.1200/JCO.2012.42.6858.

Soliman A.M., Das S., Teoh S.L. Next-Generation Biomarkers in Multiple Myeloma: Understanding the Molecular Basis for Potential Use in Diagnosis and Prognosis. Int J Mol Sci. 2021; 22(14): 7470. doi: 10.3390/ijms22147470.

Campo C., da Silva Filho M.I., Weinhold N., Mahmoudpour S.H., Goldschmidt H., Hemminki K., Merz M., Försti A. Bortezomib-induced peripheral neuropathy: A genome-wide association study on multiple myeloma patients. Hematol Oncol. 2018; 36(1): 232–7. doi: 10.1002/hon.2391.

Barrio S., Munawar U., Zhu Y.X., Giesen N., Shi C.X., Viá M.D., Sanchez R., Bruins L., Demler T., Müller N., Haertle L., Garitano A., Steinbrunn T., Danhof S., Cuenca I., Barrio-Garcia C., Braggio E., Rosenwald A., Martinez-Lopez J., Rasche L., Raab M.S., Stewart A.K., Einsele H., Stühmer T., Kortüm K.M. IKZF1/3 and CRL4CRBN E3 ubiquitin ligase mutations and resistance to immunomodulatory drugs in multiple myeloma. Haematologica. 2020; 105(5): 237–41. doi: 10.3324/haematol.2019.217943.

Fonseca R., Barlogie B., Bataille R., Bastard C., Bergsagel P.L., Chesi M., Davies F.E., Drach J., Greipp P.R., Kirsch I.R., Kuehl W.M., Hernandez J.M., Minvielle S., Pilarski L.M., Shaughnessy J.D., Stewart A.K., Avet-Loiseau H. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res. 2004; 64(4): 1546–58. doi: 10.1158/0008-5472. can-03-2876.

Walker B.A., Wardell C.P., Murison A., Boyle E.M., Begum D.B., Dahir N.M., Proszek P.Z., Melchor L., Pawlyn C., Kaiser M.F., Johnson D.C., Qiang Y.W., Jones J.R., Cairns D.A., Gregory W.M., Owen R.G., Cook G., Drayson M.T., Jackson G.H., Davies F.E., Morgan G.J. APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Nat Commun. 2015; 6: 6997. doi: 10.1038/ncomms7997.

Walker B.A., Wardell C.P., Brioli A., Boyle E., Kaiser M.F., Begum D.B., Dahir N.B., Johnson D.C., Ross F.M., Davies F.E., Morgan G.J. Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients. Blood Cancer J. 2014; 4(3): 191. doi: 10.1038/bcj.2014.13.

Pawlyn C., Melchor L., Murison A., Wardell C.P., Brioli A., Boyle E.M., Kaiser M.F., Walker B.A., Begum D.B., Dahir N.B., Proszek P., Gregory W.M., Drayson M.T., Jackson G.H., Ross F.M., Davies F.E., Morgan G.J. Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations. Blood. 2015; 125(5): 831–40. doi: 10.1182/blood-2014-07-584268.

Aksenova A.Y., Zhuk A.S., Lada A.G., Zotova I.V., Stepchenkova E.I., Kostroma I.I., Gritsaev S.V., Pavlov Y.I. Genome Instability in Multiple Myeloma: Facts and Factors. Cancers (Basel). 2021; 13(23): 5949. doi: 10.3390/cancers13235949.

Shaughnessy J.D., Zhan F., Burington B.E., Huang Y., Colla S., Hanamura I., Stewart J.P., Kordsmeier B., Randolph C., Williams D.R., Xiao Y., Xu H., Epstein J., Anaissie E., Krishna S.G., Cottler-Fox M., Hollmig K., Mohiuddin A., Pineda-Roman M., Tricot G., van Rhee F., Sawyer J., Alsayed Y., Walker R., Zangari M., Crowley J., Barlogie B. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007; 109(6): 2276–84. doi: 10.1182/blood-2006-07-038430.

Hose D., Rème T., Hielscher T., Moreaux J., Messner T., Seckinger A., Benner A., Shaughnessy J.D., Barlogie B., Zhou Y., Hillengass J., Bertsch U., Neben K., Möhler T., Rossi J.F., Jauch A., Klein B., Goldschmidt H. Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma. Haematologica. 2011; 96(1): 87–95. doi: 10.3324/haematol.2010.030296.

Hermansen N.E., Borup R., Andersen M.K., Vangsted A.J., Clausen N.T., Kristensen D.L., Nielsen F.C., Gimsing P. Gene expression risk signatures maintain prognostic power in multiple myeloma despite microarray probe set translation. Int J Lab Hematol. 2016; 38(3): 298–307. doi: 10.1111/ijlh.12486.

Chng W.J., Chung T.H., Kumar S., Usmani S., Munshi N., AvetLoiseau H., Goldschmidt H., Durie B., Sonneveld P. Gene signature combinations improve prognostic stratification of multiple myeloma patients. Leukemia. 2016; 30(5): 1071–8. doi: 10.1038/leu.2015.341.

Munshi N.C., Anderson K.C., Bergsagel P.L., Shaughnessy J., Palumbo A., Durie B., Fonseca R., Stewart A.K., Harousseau J.L., Dimopoulos M., Jagannath S., Hajek R., Sezer O., Kyle R., Sonneveld P., Cavo M., Rajkumar S.V., San Miguel J., Crowley J., Avet-Loiseau H.; International Myeloma Workshop Consensus Panel 2. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood. 2011; 117(18): 4696–700. doi: 10.1182/blood-2010-10-300970.

Chanukuppa V., Taware R., Taunk K., Chatterjee T., Sharma S., Somasundaram V., Rashid F., Malakar D., Santra M.K., Rapole S. Proteomic Alterations in Multiple Myeloma: A Comprehensive Study Using Bone Marrow Interstitial Fluid and Serum Samples. Front Oncol. 2021; 10. doi: 10.3389/fonc.2020.566804.

Łuczak M., Kubicki T., Rzetelska Z., Szczepaniak T., PrzybyłowiczChalecka A., Ratajczak B., Czerwińska-Rybak J., Nowicki A., Joks M., Jakubowiak A., Komarnicki M., Dytfeld D. Comparative proteomic profiling of sera from patients with refractory multiple myeloma reveals potential biomarkers predicting response to bortezomib-based therapy. Pol Arch Intern Med. 2017; 127(6): 392–400. doi: 10.20452/pamw.4032.

Rajpal R., Dowling P., Meiller J., Clarke C., Murphy W.G., O'Connor R., Kell M., Mitsiades C., Richardson P., Anderson K.C., Clynes M., O'Gorman P. A novel panel of protein biomarkers for predicting response to thalidomide-based therapy in newly diagnosed multiple myeloma patients. Proteomics. 2011; 11(8): 1391–402. doi: 10.1002/pmic.201000471.

Ismail N.H., Mussa A., Al-Khreisat M.J., Mohamed Yusoff S., Husin A., Johan M.F. Proteomic Alteration in the Progression of Multiple Myeloma: A Comprehensive Review. Diagnostics (Basel). 2023; 13(14): 2328. doi: 10.3390/diagnostics13142328.

Hillen F., Griffioen A.W. Tumour vascularization: sprouting angiogenesis and beyond. Cancer Metastasis Rev. 2007; 26(3–4): 489–502. doi: 10.1007/s10555-007-9094-7.

Carmeliet P. Angiogenesis in life, disease and medicine. Nature. 2005; 438(7070): 932–6. doi: 10.1038/nature04478.

Feng Q., Guo P., Wang J., Zhang X., Yang H.C., Feng J.G. High expression of SDF-1 and VEGF is associated with poor prognosis in patients with synovial sarcomas. Exp Ther Med. 2018; 15(3): 2597–603. doi: 10.3892/etm.2018.5684.

Khan R., Sharma M., Kumar L., Husain S.A., Sharma A. Interrelationship and expression profiling of cyclooxygenase and angiogenic factors in Indian patients with multiple myeloma. Ann Hematol. 2013; 92(1): 101–9. doi: 10.1007/s00277-012-1572-5.

Khan R., Sharma M., Kumar L., Husain S.A., Sharma A. Cinnamon extract exhibits potent anti-proliferative activity by modulating angiogenesis and cyclooxygenase in myeloma cells. J Herb Med. 2016; 6(3): 149–56. doi: 10.1016/j.hermed.2016.04.001.

Sezer O., Niemöller K., Eucker J., Jakob C., Kaufmann O., Zavrski I., Dietel M., Possinger K. Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma. Ann Hematol. 2000; 79(10): 574–7. doi: 10.1007/s002770000236.

Kawano Y., Roccaro A.M., Ghobrial I.M., Azzi J. Multiple Myeloma and the Immune Microenvironment. Curr Cancer Drug Targets. 2017; 17(9): 806–18. doi: 10.2174/1568009617666170214102301.

Kamimura N., Wolf A.M., Iwai Y. Development of Cancer Immunotherapy Targeting the PD-1 Pathway. J Nippon Med Sch. 2019; 86(1): 10–4. doi: 10.1272/jnms.JNMS.2019_86-2.

Zhang X., Liu L., Zhou S., Zhao K., Song Z., Hu G., Zhang T., Li Y., Qiu L., Li L., Qian Z., Meng B., Pan Y., Ren X., Wang X., Zhang H., Fu K. Plasma soluble programmed death ligand 1 levels predict clinical response in peripheral T-cell lymphomas. Hematol Oncol. 2019; 37(3): 270–6. doi: 10.1002/hon.2636.

Braga W.M., da Silva B.R., de Carvalho A.C., Maekawa Y.H., Bortoluzzo A.B., Rizzatti E.G., Atanackovic D., Colleoni G.W. FOXP3 and CTLA4 overexpression in multiple myeloma bone marrow as a sign of accumulation of CD4(+) T regulatory cells. Cancer Immunol Immunother. 2014; 63(11): 1189–97. doi: 10.1007/s00262-014-1589-9.

Dhodapkar M.V. MGUS to myeloma: a mysterious gammopathy of underexplored significance. Blood. 2016; 128(23): 2599–606. doi: 10.1182/blood-2016-09-692954.

Nooka A.K., Wang M.L., Yee A.J., Kaufman J.L., Bae J., Peterkin D., Richardson P.G., Raje N.S. Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma: A Nonrandomized Clinical Trial. JAMA Oncol. 2018; 4(12). doi: 10.1001/jamaoncol.2018.3267.

Paiva B., Azpilikueta A., Puig N., Ocio E.M., Sharma R., Oyajobi B.O., Labiano S., San-Segundo L., Rodriguez A., Aires-Mejia I., Rodriguez I., Escalante F., de Coca A.G., Barez A., San Miguel J.F., Melero I. PD-L1/ PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma. Leukemia. 2015; 29(10): 2110–3. doi: 10.1038/leu.2015.79.

Siegel D.S., Schiller G.J., Samaras C., Sebag M., Berdeja J., Ganguly S., Matous J., Song K., Seet C.S., Talamo G., Acosta-Rivera M., Bar M., Quick D., Anz B., Fonseca G., Reece D., Pierceall W.E., Chung W., Zafar F., Agarwal A., Bahlis N.J. Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment. Leukemia. 2020; 34(12): 3286–97. doi: 10.1038/s41375-0200813-1.

Ali Syeda Z., Langden S.S.S., Munkhzul C., Lee M., Song S.J. Regulatory Mechanism of MicroRNA Expression in Cancer. Int J Mol Sci. 2020; 21(5): 1723. doi: 10.3390/ijms21051723.

Rossi M., Amodio N., Di Martino M.T., Tagliaferri P., Tassone P., Cho W.C. MicroRNA and multiple myeloma: from laboratory findings to translational therapeutic approaches. Curr Pharm Biotechnol. 2014; 15(5): 459–67. doi: 10.2174/1389201015666140519104743.

Chen D., Yang X., Liu M., Zhang Z., Xing E. Roles of miRNA dysregulation in the pathogenesis of multiple myeloma. Cancer Gene Ther. 2021; 28(12): 1256–68. doi: 10.1038/s41417-020-00291-4.

Doan M., Vorobjev I., Rees P., Filby A., Wolkenhauer O., Goldfeld A.E., Lieberman J., Barteneva N., Carpenter A.E., Hennig H. Diagnostic Potential of Imaging Flow Cytometry. Trends Biotechnol. 2018; 36(7): 649–52. doi: 10.1016/j.tibtech.2017.12.008.

Wolff H.B., Steeghs E.M.P., Mfumbilwa Z.A., Groen H.J.M., Adang E.M., Willems S.M., Grünberg K., Schuuring E., Ligtenberg M.J.L., Tops B.B.J., Coupé V.M.H. Cost-Effectiveness of Parallel Versus Sequential Testing of Genetic Aberrations for Stage IV Non-Small-Cell Lung Cancer in the Netherlands. JCO Precis Oncol. 2022; 6. doi: 10.1200/PO.22.00201.

Yao Q., Bai Y., Orfao A., Chim C.S. Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma. Front Oncol. 2019; 9: 449. doi: 10.3389/fonc.2019.00449.

Yao Q., Bai Y., Orfao A., Kumar S., Chim C.S. Upgraded Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma. J Mol Diagn. 2020; 22(5): 679–84. doi: 10.1016/j.jmoldx.2020.02.005.

Mishima Y., Paiva B., Shi J., Park J., Manier S., Takagi S., Massoud M., Perilla-Glen A., Aljawai Y., Huynh D., Roccaro A.M., Sacco A., Capelletti M., Detappe A., Alignani D., Anderson K.C., Munshi N.C., Prosper F., Lohr J.G., Ha G., Freeman S.S., Van Allen E.M., Adalsteinsson V.A., Michor F., San Miguel J.F., Ghobrial I.M. The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma. Cell Rep. 2017; 19(1): 218–24. doi: 10.1016/j.celrep.2017.03.025.

Kazandjian D. Multiple myeloma epidemiology and survival: A unique malignancy. Semin Oncol. 2016; 43(6): 676–81. doi: 10.1053/j.seminoncol.2016.11.004.

Xu J., Xu P., Han Q., Sun J., Chen B., Dong X. Socioeconomic status-based survival disparities and nomogram prediction for patients with multiple myeloma: Results from American and Chinese populations. Front Oncol. 2022; 12. doi: 10.3389/fonc.2022.941714.

Callander N.S., Baljevic M., Adekola K., Anderson L.D., Campagnaro E., Castillo J.J., Costello C., Devarakonda S., Elsedawy N., Faiman M., Garfall A., Godby K., Hillengass J., Holmberg L., Htut M., Huff C.A., Hultcrantz M., Kang Y., Larson S., Liedtke M., Martin T., Omel J., Sborov D., Shain K., Stockerl-Goldstein K., Weber D., Berardi R.A., Kumar R., Kumar S.K. NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022. J Natl Compr Canc Netw. 2022; 20(1): 8–19. doi: 10.6004/jnccn.2022.0002.

Rajkumar S.V. Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol. 2016; 91(7): 719–34. doi: 10.1002/ajh.24402.

Fechtner K., Hillengass J., Delorme S., Heiss C., Neben K., Goldschmidt H., Kauczor H.U., Weber M.A. Staging monoclonal plasma cell disease: comparison of the Durie-Salmon and the Durie-Salmon PLUS staging systems. Radiology. 2010; 257(1): 195–204. doi: 10.1148/radiol.10091809.

The authors declare that there are no conflicts of interest present.